Maccura Biotechnology Co.Ltd (300463.SZ)
CNY 11.37
(-0.26%)
CNY 11.37
(-0.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.18 Billion CNY | 8.22% |
| 2022 | 1.06 Billion CNY | 5.77% |
| 2021 | 1 Billion CNY | 15.61% |
| 2020 | 868.31 Million CNY | 0.27% |
| 2019 | 865.97 Million CNY | 21.32% |
| 2018 | 713.8 Million CNY | 37.79% |
| 2017 | 518.05 Million CNY | 26.76% |
| 2016 | 408.67 Million CNY | 40.13% |
| 2015 | 291.62 Million CNY | 19.6% |
| 2014 | 243.83 Million CNY | 35.75% |
| 2013 | 179.62 Million CNY | 37.01% |
| 2012 | 131.1 Million CNY | 12.53% |
| 2011 | 116.5 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 217.88 Million CNY | -44.34% |
| 2024 Q2 | 213.21 Million CNY | -2.15% |
| 2024 Q3 | 266.68 Million CNY | 36.21% |
| 2023 Q4 | 391.43 Million CNY | 44.05% |
| 2023 Q1 | 217.54 Million CNY | -39.01% |
| 2023 Q2 | 268.22 Million CNY | 23.3% |
| 2023 Q3 | 271.72 Million CNY | 1.31% |
| 2023 FY | 1.14 Billion CNY | 8.22% |
| 2022 Q2 | 234.37 Million CNY | 5.18% |
| 2022 Q1 | 222.82 Million CNY | -30.88% |
| 2022 FY | 1.06 Billion CNY | 5.77% |
| 2022 Q4 | 356.68 Million CNY | 43.93% |
| 2022 Q3 | 247.82 Million CNY | 5.74% |
| 2021 Q1 | 222.55 Million CNY | -34.04% |
| 2021 Q4 | 322.38 Million CNY | 21.51% |
| 2021 FY | 1 Billion CNY | 15.61% |
| 2021 Q3 | 265.31 Million CNY | 37.05% |
| 2021 Q2 | 193.58 Million CNY | -13.02% |
| 2020 Q1 | 142.14 Million CNY | -49.2% |
| 2020 FY | 868.31 Million CNY | 0.27% |
| 2020 Q4 | 337.41 Million CNY | 57.29% |
| 2020 Q3 | 214.52 Million CNY | 23.12% |
| 2020 Q2 | 174.23 Million CNY | 22.58% |
| 2019 Q4 | 279.82 Million CNY | 39.85% |
| 2019 Q3 | 200.09 Million CNY | -0.31% |
| 2019 Q2 | 200.71 Million CNY | 8.29% |
| 2019 FY | 865.97 Million CNY | 21.32% |
| 2019 Q1 | 185.34 Million CNY | -16.21% |
| 2018 Q4 | 221.21 Million CNY | 13.89% |
| 2018 Q2 | 166.07 Million CNY | 25.55% |
| 2018 Q1 | 132.27 Million CNY | -34.91% |
| 2018 FY | 713.8 Million CNY | 37.79% |
| 2018 Q3 | 194.23 Million CNY | 16.95% |
| 2017 Q1 | 91.32 Million CNY | -34.08% |
| 2017 Q2 | 102.25 Million CNY | 11.97% |
| 2017 FY | 518.05 Million CNY | 26.76% |
| 2017 Q3 | 121.25 Million CNY | 18.58% |
| 2017 Q4 | 203.22 Million CNY | 67.6% |
| 2016 Q3 | 103.15 Million CNY | 10.71% |
| 2016 FY | 408.67 Million CNY | 40.13% |
| 2016 Q4 | 138.52 Million CNY | 34.29% |
| 2016 Q2 | 93.17 Million CNY | 26.22% |
| 2016 Q1 | 73.81 Million CNY | -28.38% |
| 2015 Q2 | 59.25 Million CNY | 13.5% |
| 2015 Q1 | 52.2 Million CNY | -38.18% |
| 2015 FY | 291.62 Million CNY | 19.6% |
| 2015 Q4 | 103.07 Million CNY | 33.68% |
| 2015 Q3 | 77.1 Million CNY | 30.13% |
| 2014 FY | 243.83 Million CNY | 35.75% |
| 2014 Q4 | 84.44 Million CNY | 39.47% |
| 2014 Q1 | 45.98 Million CNY | 0.0% |
| 2014 Q3 | 60.54 Million CNY | 14.55% |
| 2014 Q2 | 52.85 Million CNY | 14.95% |
| 2013 FY | 179.62 Million CNY | 37.01% |
| 2012 FY | 131.1 Million CNY | 12.53% |
| 2011 FY | 116.5 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 3.35 Billion CNY | 64.793% |
| Hangzhou Tigermed Consulting Co., Ltd. | 358.41 Million CNY | -229.343% |
| Dirui Industrial Co.,Ltd. | 387.16 Million CNY | -204.888% |
| Beijing Strong Biotechnologies, Inc. | 702.74 Million CNY | -67.973% |
| Medicalsystem Biotechnology Co., Ltd. | 562.06 Million CNY | -110.015% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.17 Billion CNY | -0.428% |
| Guangdong Hybribio Biotech Co.,Ltd. | 631.43 Million CNY | -86.942% |
| BGI Genomics Co., Ltd. | 1.93 Billion CNY | 39.13% |
| Amoy Diagnostics Co., Ltd. | 574.96 Million CNY | -105.302% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 479.96 Million CNY | -145.936% |